G
Monte Rosa Therapeutics D
D
GLUE
17.960
USD
-0.66
(-3.54%)
Market Closed
Volume
29,665
EPS
-1
Div Yield
-
P/E
56
Market Cap
1,369,319,988
Title: Monte Rosa Therapeutics
Sector: Healthcare
Industry: Biotechnology
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

